{
    "2018-04-25": [
        [
            {
                "time": "2018-04-15",
                "original_text": "Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release",
                "features": {
                    "keywords": [
                        "analysts",
                        "Sanofi",
                        "earnings release"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-20",
                "original_text": "A Review of Novo Nordisk’s Modern Insulin",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "modern insulin",
                        "review"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-02-25",
                "original_text": "Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "new-generation insulins",
                        "growth driver"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Novo Nordisk’s Xultophy Expected to See High Growth in 2018",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Xultophy",
                        "high growth"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}